Recent Comments

Comment RSS

Transplant News and Research RSS Feed - Transplant News and Research

New hope for patients with liver cancer

21. November 2009 01:15
In patients with unresectable (unable to be removed by surgery) liver cancer, an interventional radiology procedure called triple-drug transcatheter arterial chemoemobolization (TACE) followed by a liver transplant may significantly increase a patient's chance of long-term survival, according to a study published in the December issue of the American Journal of Roentgenology. [More]

Posted in: Medical Procedure News | Medical Condition News

Tags: , , , , ,

Children with kidney disease likely to have "masked" hypertension

20. November 2009 23:47
Spot blood pressure readings in children with chronic kidney disease often fail to detect hypertension - even during doctor's office visits - increasing a child's risk for serious heart problems, according to research from Johns Hopkins Children's Center and other institutions. A report of the findings appears online in the Journal of American Society of Nephrology. [More]

NHLBI-supported research shares new strategies on hypertension, heart defect and air pollution

20. November 2009 05:00
New education strategies for better controlling hypertension and research suggesting a possible link between short-term and long-term exposure to air pollution and increased risk of constricted blood vessels are among the research highlights from studies supported by the National Heart, Lung, and Blood Institute (NHLBI) at the American Heart Association's 2009 Scientific Sessions in Orlando held Nov. 14-18. [More]

Sleep apnea is associated with cardiovascular risk factors among kidney transplant patients

20. November 2009 00:14
Sleep apnea is common in individuals who receive a kidney transplant and is associated with increased risk of high blood pressure, heart disease or stroke, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). [More]

ISCO, Scripps Research Institute collaborate in study of parthenogenetic stem cells

19. November 2009 08:23
International Stem Cell Corporation, announced today that it is collaborating with renowned stem cell researcher Jeanne F. Loring, Ph.D., and the Scripps Research Institute (La Jolla, CA) to study parthenogenetic stem cells and potentially therapeutic cells that can be derived from them. [More]

Posted in: Medical Science News

Tags: , , , ,

HealthGrades identifies top-rated hospital organ-transplantation centers

19. November 2009 07:28
The top-rated hospitals for organ transplantation are being identified for the first time today by HealthGrades, the leading independent healthcare ratings organization. Based on patient outcomes, quality data for each of the 266 hospitals that perform transplants have been made public at www.healthgrades.com to help patients in need of kidney, lung, heart and liver transplants research and choose a transplant center. [More]

Posted in: Healthcare News

Tags: , ,

Continuous flow heart pump improves survival rates in heart failure patients than current pulsating models

19. November 2009 06:38
A new, continuous flow heart pump, or left ventricular assist device (LVAD), delivered better two-year survival in advanced heart failure patients than the current pulsatile model, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009. [More]

Posted in: Device / Technology News | Medical Condition News

Tags: , , ,

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

19. November 2009 00:49
Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus. [More]

Minimally invasive procedures drive the global uro-gynecological surgical devices market

18. November 2009 07:50
World uro-gynecological surgical devices market is driven by the growing acceptance of minimally invasive procedures as a convenient alternative option to hysterectomy. [More]

Phase 2/3 study results of Genzyme's APB announced

18. November 2009 07:06
Genzyme Corporation today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo. However, the APB did not show a significant improvement in phosphate lowering compared to Genzyme’s Renvela® (sevelamer carbonate). [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , ,

New generation of implanted devices help a failing heart function properly

18. November 2009 04:27
A new generation of implanted devices that help a failing heart function properly is significantly more effective than the previous version, making these new devices an appropriate permanent therapy for many of the more than 5 million Americans who suffer from heart failure. [More]

Posted in: Device / Technology News

Tags: , , , ,

Report on the U.S. cardiac surgery devices market

18. November 2009 01:46
In 2008, the U.S. market for cardiac surgery devices was valued at over $1.6 billion, representing growth of nearly 7% over 2007. [More]

Transplanting people's own stem cells into heart muscle lessens pain and improves ability to walk

18. November 2009 01:17
The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ability to walk. The transplant subjects also experienced fewer deaths than those who didn't receive stem cells. [More]

Posted in: Medical Procedure News | Medical Condition News

Tags: , , , , , ,

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

17. November 2009 10:42
Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were presented today at the American Heart Association’s Scientific Sessions. [More]

Genzyme receives FDA complete response letter for its Lumizyme marketing application

17. November 2009 03:42
Genzyme Corporation announced today that it has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase alfa) for the treatment of Pompe disease. In its letter, the agency stated that satisfactory resolution of deficiencies related to the Allston Landing manufacturing plant are required before the Lumizyme application can be approved. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.